Teva sets goals of $31 billion revenues and non-GAAP net income of $6.8 billion by 2015

During its investor meeting in New York, USA, yesterday, Israeli generics giant Teva Pharmaceutical Industries updated on its strategy, highlighting key opportunities for growth and announcing its long-term goals of reaching revenues of $31 billion and non-GAAP net income of $6.8 billion, or 22% of revenues, by 2015.

"In the years to come, Teva will seek to extend our global leadership and deliver profitable growth, doubling our revenues by 2015 and reaching net income margins of 22%," said Shlomo Yanai, Teva's president and chief executive. "Our core business, generics, will continue to drive our growth. At the same time, we will continue to expand our branded business, further leveraging the diversity of our balanced business model,' he told the meeting

The growing worldwide demand for generic pharmaceuticals - as a means to expand access to affordable high-quality medicine and control health care costs - will continue to drive the growth of Teva's core business in the USA and globally. A significant portion of this growth is expected to come from those European and international markets that are currently characterized by low generic penetration rates.